title: [Optimization of the therapy of atopic dermatitis by means of immunotherapy].
abstract: Taking into account disturbances in the functioning of the immune system in atopic dermatitis (AD) and the potentiating role of staphylococcal and other infections, the possibility of the optimization of the therapy of AD with the use of preparations having immunomodulating action and immunogenic activity is proposed. In the complex therapy of AD in children we used polycomponent vaccine Immunovac B-4, introduced intranasally and orally. Under the influence of immunotherapy the clinical characteristics of the patients had pronounced positive dynamics. A considerable decrease in the spread of the process, the degree of its severity and subjective symptoms was noted shortly after the course of vaccine treatment. Simultaneously the SCORAD index dropped from 64.5 to 39.4. During the later period of observation further decrease in the severity of the course of AD in children occurred, and the minimal characteristics were observed in 6 months of observation. At that time the SCORAD index fell to 19.9 +/- 1.34. The volume of pharmacotherapy and the number of acute respiratory infections considerably decreased, the positive dynamics of the quantitative and qualitative composition of the intestinal microflora was noted. The prolonged immunotherapeutic effect of the polycomponent vaccine made it possible to recommend the vaccine for the optimization of the therapy of AD.
authors.forename: O E
authors.initials: OE
authors.lastname: Nemykina
authors.forename: N B
authors.initials: NB
authors.lastname: Egorova
authors.forename: B V
authors.initials: BV
authors.lastname: Shcherbakova
authors.forename: E A
authors.initials: EA
authors.lastname: Kurbatova
authors.forename: I B
authors.initials: IB
authors.lastname: Semenova
authors.forename: V N
authors.initials: VN
authors.lastname: Efremova
authors.forename: I M
authors.initials: IM
authors.lastname: Gruber
authors.forename: B F
authors.initials: BF
authors.lastname: Semenov
mesh_terms: D000281:Administration, Intranasal; D000284:Administration, Oral; D000293:Adolescent; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology; D001644:Bifidobacterium / Q000302:isolation & purification; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D006801:Humans; D016233:Immunotherapy, Active; D007422:Intestines / Q000276:immunology / Q000382:microbiology; D007778:Lactobacillus / Q000302:isolation & purification; D012720:Severity of Illness Index; D016896:Treatment Outcome; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology
chemical_list: D001428:Bacterial Vaccines; C088865:VP-4 vaccine; D017778:Vaccines, Combined